Integrity Alliance LLC. Makes New Investment in Royalty Pharma PLC $RPRX

Integrity Alliance LLC. purchased a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 9,377 shares of the biopharmaceutical company’s stock, valued at approximately $547,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Greenleaf Trust boosted its position in shares of Royalty Pharma by 5.5% in the 3rd quarter. Greenleaf Trust now owns 4,385 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 228 shares in the last quarter. Glenmede Trust Co. NA raised its position in Royalty Pharma by 3.4% during the first quarter. Glenmede Trust Co. NA now owns 7,812 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 254 shares during the last quarter. MBL Wealth LLC lifted its holdings in shares of Royalty Pharma by 7.3% in the third quarter. MBL Wealth LLC now owns 3,908 shares of the biopharmaceutical company’s stock valued at $228,000 after purchasing an additional 266 shares in the last quarter. Bessemer Group Inc. lifted its holdings in shares of Royalty Pharma by 34.7% in the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 282 shares in the last quarter. Finally, CoreCap Advisors LLC grew its position in shares of Royalty Pharma by 89.2% in the second quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 413 shares during the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. TD Cowen raised their price objective on shares of Royalty Pharma from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. Morgan Stanley increased their target price on Royalty Pharma from $65.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. JPMorgan Chase & Co. raised their price target on Royalty Pharma from $58.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Bank of America reissued a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. Finally, Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, September 14th. Eight analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $63.29.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 4,126 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $57.10, for a total value of $235,594.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the transaction, the executive vice president directly owned 270,401 shares in the company, valued at approximately $15,826,570.53. This represents a 27.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 208,252 shares of company stock valued at $12,324,407 over the last ninety days. 18.84% of the stock is owned by corporate insiders.

Royalty Pharma Stock Performance

Shares of NASDAQ RPRX opened at $67.30 on Friday. The company has a market cap of $38.70 billion, a PE ratio of 56.08, a price-to-earnings-growth ratio of 1.34 and a beta of 0.37. Royalty Pharma PLC has a 12 month low of $37.31 and a 12 month high of $69.77. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.29 and a quick ratio of 2.80. The company has a 50-day simple moving average of $60.82 and a 200-day simple moving average of $53.81.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.05. The business had revenue of $674.14 million during the quarter, compared to analyst estimates of $758.93 million. Royalty Pharma had a net margin of 25.68% and a return on equity of 30.04%. On average, equities analysts anticipate that Royalty Pharma PLC will post 5.36 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $0.2350 per share. The ex-dividend date is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. Royalty Pharma’s dividend payout ratio (DPR) is 78.33%.

About Royalty Pharma

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding.

The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.

Founded in 1996 by Pablo Legorreta, the company became publicly listed in 2020.